Finanzas de Surgery Partners Inc (SGRY)SGRYSurgery Partners Inc

Surgery Partners, Inc. (SGRY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Patient service revenues, accounting for 97.3% of total sales, equivalent to $826.10M. Another important revenue stream is Other service revenues. Understanding this composition is critical for investors evaluating how SGRY navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Surgery Partners, Inc. maintains a gross margin of 17.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.18%, while the net margin is 3.50%. These profitability ratios, combined with a Return on Equity (ROE) of -5.18%, provide a clear picture of how effectively SGRY converts its operational activities into shareholder value.

In the context of the broader market, SGRY competes directly with industry leaders such as ARDT and BKD. With a market capitalization of $1.79B, it holds a significant position in the sector. When comparing efficiency, SGRY's gross margin of 17.78% stands against ARDT's 55.77% and BKD's 18.74%. Such benchmarking helps identify whether Surgery Partners, Inc. is trading at a premium or discount relative to its financial performance.

Surgery Partners has shown fluctuating financial performance with total revenues expected to be between $3.35 billion to $3.45 billion for 2026, but it has also reported net income losses in recent quarters, including a loss of $35.9 million in Q1 2026 and $15 million in Q2 2026. Gross margins have been inconsistent, with the latest figure at 17.78%.